Golden State Wealth Management LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 623.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 658 shares of the pharmaceutical company’s stock after purchasing an additional 567 shares during the quarter. Golden State Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $319,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the business. Capital World Investors grew its stake in shares of Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after purchasing an additional 1,514,993 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company’s stock worth $9,366,113,000 after purchasing an additional 98,654 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after purchasing an additional 1,426,746 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after purchasing an additional 1,117,214 shares during the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in shares of Vertex Pharmaceuticals by 23.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company’s stock worth $1,519,302,000 after purchasing an additional 704,575 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.
Vertex Pharmaceuticals Price Performance
VRTX stock opened at $441.30 on Friday. The stock has a market capitalization of $113.33 billion, a PE ratio of -112.58 and a beta of 0.41. The company’s 50-day moving average is $454.50 and its 200-day moving average is $458.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 11th. Leerink Partners reaffirmed a “market perform” rating and set a $503.00 price target (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada set a $420.00 price target on shares of Vertex Pharmaceuticals and gave the company a “sector perform” rating in a research report on Tuesday, June 17th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $511.62.
Check Out Our Latest Report on VRTX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- What Are Dividend Achievers? An Introduction
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- CD Calculator: Certificate of Deposit Calculator
- 3 Stocks Hitting All-Time Highs With More Room to Run
- What Are Dividend Challengers?
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.